Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Accounts Payables (2019 - 2025)

Biodesix (BDSX) has disclosed Accounts Payables for 7 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 40.38% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Dec 2025, up 40.38%, and an annual FY2025 reading of $3.1 million, up 40.38% over the prior year.
  • Accounts Payables was $3.1 million for Q4 2025 at Biodesix, down from $3.6 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $3.7 million in Q1 2021 and bottomed at $1.2 million in Q2 2021.
  • Average Accounts Payables over 5 years is $2.5 million, with a median of $2.4 million recorded in 2024.
  • The sharpest move saw Accounts Payables tumbled 81.46% in 2021, then soared 105.57% in 2024.
  • Year by year, Accounts Payables stood at $1.7 million in 2021, then grew by 1.38% to $1.7 million in 2022, then surged by 73.83% to $2.9 million in 2023, then dropped by 25.09% to $2.2 million in 2024, then surged by 40.38% to $3.1 million in 2025.
  • Business Quant data shows Accounts Payables for BDSX at $3.1 million in Q4 2025, $3.6 million in Q3 2025, and $3.0 million in Q2 2025.